astrazeneca
Cholesterol-lowering medication accelerates depletion of plaque in arteries
In a new study, NYU Langone Medical Center researchers have discovered how cholesterol-lowering drugs called statins promote the breakdown of plaque in the arteries. The study was published online by the journal PLoS One on December 6, 2011.
The findi…
Potential new treatment for people with manic depression
Drug company AstraZeneca said it has submitted an application to the U.S. Food and Drug Administration for approval of quetiapine (Seroquel) as a treatment for acute mania associated with bipolar disorder, or manic-depressive illness. The application follows the completion of a clinical trial programme in bipolar disorder undertaken by the company which reportedly found quetiapine effective as a treatment of acute mania on two levels: as monotherapy (i.e to be prescribed on its own) and as adjunctive therapy with standard mood stabilising medication. These clinical trials have delivered strong and positive results in both the monotherapy and adjunctive therapy studies, which confirm quetiapine to be an ideal first line therapy for the treatment of acute mania associated with bipolar disorder, the company said.